Amyloidosis is a systemic disease caused by the deposition of misfolded proteins. Cardiac involvement is a major cause of morbidity and mortality, especially in the light chain (AL) and transthyretin (ATTR) forms. Amyloidosis usually presents as a restrictive cardiomyopathy with progressive systolic/ diastolic dysfunction and arrhythmias but is often misdiagnosed as hypertrophic or hypertensive...

Psoriasis is a chronic, recurrent, inflammatory and common skin disease of unknown aetiology. Amyloidosis defined as heterogeneous group diseases in which generally soluble plasma proteins accumulate the extracellular space insoluble abnormal fibrils. Type AA amyloidosis late severe complication chronic disorders some infections. Although psoriasis disease, development rare. Herein, we presente...

BACKGROUND Primary amyloidosis of the breast is an unusual benign disease that mostly occurs in postmenopausal elderly women. Amyloidosis is the deposition of amorphous protein within tissues. Breast biopsy is necessary to make a definite diagnosis in order to avoid unnecessary surgical methods. Localized primary amyloidosis of the breast has a good prognosis. However, secondary amyloidosis is ...

Amyloidosis is a family of disorders of the immune system in which one or more organs in the body accumulate amyloid. There are four different forms of amyloidosis: systemic amyloid light chain (AL) amyloidosis, amyloid A (AA) amyloidosis, hereditary, and senile amyloidosis. The abnormal proteins can be found as Bence-Jones proteins in urine mainly in patients with light chain (AL) amyloidosis....

Nonhematologic malignancies are rarely reported to be associated with AA amyloidosis. Although the association between renal cell carcinoma and systemic AA amyloidosis has been established, the evidence linking pulmonary cancer to AA amyloidosis is scarce. Here, a case of biopsy-proven renal AA amyloidosis complicated with nephrotic syndrome associated with lung carcinoma is reported.

Amyloid fibrils from two cases of cancer-associated, systemic amyloidosis with renal cell carcinoma and mesothelioma as the respective underlying disorders were studied. The immunochemical studies suggested strongly that amyloid A comprised a principal fibril component in both cases of cancer-associated amyloidosis. This was definitively proven by amino acid sequence analyses, which revealed st...

The clinical management of amyloidosis is based on the treatment of the underlying etiology, and accurate identification of the protein causing the amyloidosis is of paramount importance. Current methods used for typing of amyloidosis such as immunohistochemistry have low specificity and sensitivity. In this study, we report the development of a highly specific and sensitive novel test for the ...

Since the first reports of amyloid being “cellulose” (reported by Virchow in the mid-1850s) and the identification of amyloid fibril ultrastructure in the late 1950s, amyloidosis has remained an enigmatic disease. However, progress in our ability to diagnose and treat amyloidosis has advanced tremendously in recent years. The use of chemotherapy and immunomodulatory agents has changed AL amyloi...

AIMS Familial amyloid polyneuropathy (FAP) is a dominantly inherited multi-system disease associated with transthyretin (TTR) mutations. Previous series have predominantly described patients with the TTR variant Val30Met (V30M), which is the most prevalent cause of FAP worldwide. Here, we report the dominant cardiac phenotype and outcome of FAP associated with TTR Thr60Ala (T60A), the most comm...